Wall Street brokerages expect Innophos Holdings, Inc. (NASDAQ:IPHS) to post earnings per share of $0.51 for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Innophos’ earnings. Innophos reported earnings of $0.52 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 1.9%. The company is scheduled to announce its next quarterly earnings report on Wednesday, February 20th.
According to Zacks, analysts expect that Innophos will report full-year earnings of $2.25 per share for the current fiscal year. For the next year, analysts forecast that the business will report earnings of $2.50 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Innophos.
Innophos (NASDAQ:IPHS) last posted its quarterly earnings results on Thursday, November 1st. The specialty chemicals company reported $0.58 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). The company had revenue of $196.93 million for the quarter, compared to the consensus estimate of $197.20 million. Innophos had a net margin of 2.49% and a return on equity of 13.30%. Innophos’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 EPS.
Large investors have recently modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new stake in shares of Innophos in the second quarter worth about $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Innophos in the third quarter worth about $208,000. Raymond James & Associates purchased a new stake in shares of Innophos in the second quarter worth about $209,000. Ifrah Financial Services Inc. purchased a new stake in shares of Innophos in the second quarter worth about $210,000. Finally, Alps Advisors Inc. purchased a new stake in shares of Innophos in the second quarter worth about $213,000. Hedge funds and other institutional investors own 95.07% of the company’s stock.
IPHS traded up $0.35 during trading on Monday, hitting $27.48. 141,000 shares of the company traded hands, compared to its average volume of 112,313. The firm has a market cap of $532.19 million, a P/E ratio of 11.17 and a beta of 1.21. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.36 and a current ratio of 2.79. Innophos has a one year low of $26.44 and a one year high of $50.40.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 16th will be given a dividend of $0.48 per share. The ex-dividend date is Thursday, November 15th. This represents a $1.92 dividend on an annualized basis and a yield of 6.99%. Innophos’s dividend payout ratio is presently 78.05%.
Innophos Company Profile
Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.
Further Reading: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.